Prestige Consumer Healthcare (NYSE:PBH) Shares Gap Down After Earnings Miss

Prestige Consumer Healthcare Inc. (NYSE:PBH)’s share price gapped down prior to trading on Thursday following a weaker than expected earnings announcement. The stock had previously closed at $51.81, but opened at $48.06. Prestige Consumer Healthcare shares last traded at $45.5980, with a volume of 393,526 shares changing hands.

The company reported $1.23 EPS for the quarter, missing the consensus estimate of $1.39 by ($0.16). The company had revenue of $281.62 million for the quarter, compared to analyst estimates of $293.64 million. Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.The business’s revenue for the quarter was down 5.0% on a year-over-year basis. During the same period last year, the company posted $1.32 EPS. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS.

Analyst Ratings Changes

A number of equities research analysts have issued reports on PBH shares. Oppenheimer downgraded Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research report on Thursday. Jefferies Financial Group cut their price target on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating on the stock in a report on Friday, January 30th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Tuesday, April 21st. Two research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, Prestige Consumer Healthcare presently has a consensus rating of “Hold” and a consensus target price of $74.75.

Insider Transactions at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 1,207 shares of the business’s stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $54.99, for a total value of $66,372.93. Following the transaction, the vice president owned 42,820 shares in the company, valued at $2,354,671.80. The trade was a 2.74% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 1.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Prestige Consumer Healthcare

A number of institutional investors have recently made changes to their positions in PBH. Dimensional Fund Advisors LP raised its holdings in Prestige Consumer Healthcare by 3.6% in the first quarter. Dimensional Fund Advisors LP now owns 2,672,777 shares of the company’s stock valued at $158,414,000 after acquiring an additional 91,710 shares in the last quarter. State Street Corp raised its holdings in shares of Prestige Consumer Healthcare by 1.4% during the fourth quarter. State Street Corp now owns 1,992,497 shares of the company’s stock worth $122,917,000 after purchasing an additional 27,721 shares during the period. Allspring Global Investments Holdings LLC lifted its position in shares of Prestige Consumer Healthcare by 1.3% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,613,460 shares of the company’s stock worth $98,776,000 after buying an additional 21,085 shares during the last quarter. Morgan Stanley lifted its position in shares of Prestige Consumer Healthcare by 6.3% in the 4th quarter. Morgan Stanley now owns 1,202,927 shares of the company’s stock worth $74,209,000 after buying an additional 71,078 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Prestige Consumer Healthcare by 5.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 738,654 shares of the company’s stock valued at $45,568,000 after buying an additional 35,126 shares during the period. 99.95% of the stock is owned by institutional investors and hedge funds.

Prestige Consumer Healthcare Price Performance

The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.93 and a current ratio of 3.11. The company’s fifty day moving average price is $58.79 and its 200 day moving average price is $61.60. The firm has a market capitalization of $2.14 billion, a price-to-earnings ratio of 11.95, a price-to-earnings-growth ratio of 1.51 and a beta of 0.40.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).